Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ayguen Sahin"'
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0199414 (2018)
Glioblastoma multiforme (GBM) is the most aggressive and deadly form of adult brain cancer. Despite of many attempts to identify potential therapies for this disease, including promising cancer immunotherapy approaches, it remains incurable. To addre
Externí odkaz:
https://doaj.org/article/3b5c20513048402e97f6f17f4356fe83
Autor:
Prakash Sampath, Richard P. Junghans, Henry Brem, Bob S. Carter, Ayguen Sahin, Jinyuan Zhou, Saryn Doucette, Qiangzhong Ma, Anthony J. Bais, Betty Tyler, Sadhak Sengupta, Seogkyoung Kong
Purpose: Glioblastoma multiforme (GBM) remains highly incurable, with frequent recurrences after standard therapies of maximal surgical resection, radiation, and chemotherapy. To address the need for new treatments, we have undertaken a chimeric anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::250d2e5a5e9dbebb1acf0ed4e3bd9c6d
https://doi.org/10.1158/1078-0432.c.6520563
https://doi.org/10.1158/1078-0432.c.6520563
Autor:
Prakash Sampath, Richard P. Junghans, Henry Brem, Bob S. Carter, Ayguen Sahin, Jinyuan Zhou, Saryn Doucette, Qiangzhong Ma, Anthony J. Bais, Betty Tyler, Sadhak Sengupta, Seogkyoung Kong
PDF file, 136K, Bar graph representing IL2 secretion by untransduced or IL13-CAR transduced T cells upon co-culturing.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4b1ce81f8d211a975ab956a05b0e8d
https://doi.org/10.1158/1078-0432.22445802
https://doi.org/10.1158/1078-0432.22445802
Autor:
Prakash Sampath, Richard P. Junghans, Henry Brem, Bob S. Carter, Ayguen Sahin, Jinyuan Zhou, Saryn Doucette, Qiangzhong Ma, Anthony J. Bais, Betty Tyler, Sadhak Sengupta, Seogkyoung Kong
CCR Translation for This Article from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24736d1b951b2c9102f5380edbd11be9
https://doi.org/10.1158/1078-0432.22445805.v1
https://doi.org/10.1158/1078-0432.22445805.v1
Autor:
Anthony Bais, Sadhak Sengupta, Jinyuan Zhou, Richard P. Junghans, Henry Brem, Qiangzhong Ma, Saryn Doucette, Betty Tyler, Bob S. Carter, Seogkyoung Kong, Ayguen Sahin, Prakash Sampath
Publikováno v:
Clinical Cancer Research. 18:5949-5960
Purpose: Glioblastoma multiforme (GBM) remains highly incurable, with frequent recurrences after standard therapies of maximal surgical resection, radiation, and chemotherapy. To address the need for new treatments, we have undertaken a chimeric anti
Autor:
Johnny C. Akers, Ralph Weissleder, Diahnn Futalan, Carlos Sánchez, Brent Morse, Nick Marsh, David D. Gonda, Bob S. Carter, Arnab Chakravarti, Kamalakannan Palanichamy, Justin K. Scheer, Clark C. Chen, J. Dawn Waters, Eric Furfine, Ayguen Sahin, Peter Waterman, Irvith M. Carvajal
Publikováno v:
Journal of Neuro-Oncology. 110:37-48
Glioblastomas are among the most aggressive human cancers, and prognosis remains poor despite presently available therapies. Angiogenesis is a hallmark of glioblastoma, and the resultant vascularity is associated with poor prognosis. The proteins tha
Autor:
Travis S. Tierney, John T. Gale, Jeng Shin Lee, Richard C. Mulligan, Carlos Sánchez, Ayguen Sahin, Bob S. Carter, Kambiz N. Alavian
Object Although several clinical trials utilizing the adeno-associated virus (AAV) type 2 serotype 2 (2/2) are now underway, it is unclear whether this particular serotype offers any advantage over others in terms of safety or efficiency when deliver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c331b1b3418fd46a4961c149551daa7
https://europepmc.org/articles/PMC3773229/
https://europepmc.org/articles/PMC3773229/
Autor:
Elizabeth Baratta, Bob S. Carter, Oszkar Szentirmai, Ralph Weissleder, Richard C. Mulligan, Carlos Sánchez, Ning Lin, Szofia S. Bullain, Ayguen Sahin, Peter Waterman
Glioblastoma remains a significant therapeutic challenge, warranting further investigation of novel therapies. We describe an immunotherapeutic strategy to treat glioblastoma based on adoptive transfer of genetically modified T-lymphocytes (T cells)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ba36031ab822d4a39dfcf7a480e4f3
https://europepmc.org/articles/PMC2730985/
https://europepmc.org/articles/PMC2730985/
Autor:
Nicolas Wernert, Torsten Pietsch, Ali Fuat Okuducu, Pascal Knuefermann, Ayguen Sahin, Markus Velten, Jens C. Hahne
Publikováno v:
International journal of molecular medicine. 15(5)
Malignant gliomas represent the most aggressive tumours of the central nervous system and are characterised by both extensive proliferation and invasive growth. Matrix degrading proteases called matrix metalloproteinases (MMPs), particularly MMP-9, p